Balaji Amines Limited share price
NSE: BALAMINES · ISIN INE050E01027
Key numbers
- Market cap
- ₹ 7,095 Cr
- Current price
- ₹ 2,189.60
- 52-week high / low
- ₹ 2,630 / 968
- Stock P/E
- 34.7
- Book value
- ₹ 610.0
- Dividend yield
- 0.50%
- ROCE
- 11.9%
- ROE
- 8.8%
- Debt to equity
- 0.07
- Sales growth (3 yrs)
- -15.6%
- Profit growth (3 yrs)
- -19.9%
- 1-year return
- 47.6%
About Balaji Amines Limited
Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India and internationally. The company operates in two segments, Chemicals and Hotel. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, acetonitrile, dimethylcarbonate, propylene glycol, and propylene carbonate. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, choline chloride, mono-ethyl amine hydrochloride, and benzyl tri ethyl ammonium chloride; and pharma excipients, such as poly vinyl pyrrolidone. It also provides hotels, restaurants, and hospitality services. The company also exports its products to Europe, the United States, and Japan. Balaji Amines Limited was incorporated in 1988 and is headquartered in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 358 | 341 | 331 | 395 | 456 |
| Operating profit | 55 | 60 | 57 | 94 | 116 |
| Net profit | 38 | 35 | 31 | 63 | 75 |
| EPS (₹) | 11.73 | 10.67 | 9.49 | 19.99 | 23.13 |
Investor presentation summary (2026-07-29)
AI summary of the presentation · tone: Positive · source document
Key numbers
- Total Revenue 461 367 25.73% 403 14.64% 1454
- EBITDA Margin (%) 26% 17% 25% 20%
Guidance & outlook
- Particulars (Rs.Crs.) Q1FY27 Q1FY26 Y-o-Y Q4FY26 Q-o-Q FY26
- expected towards commissioning during FY27.
Growth & demand
- progressing as planned. Backed by a healthy order pipeline, improving demand and
- FY27 volume growth guided at
Margins & costs
- performance with resilient margins, supported by improving demand across key end-user
- Total Revenue (INR Cr) EBITDA (INR Cr)
Capex & expansion
- Our NMM and Acetonitrile expansion projects remain firmly on track for commissioning by
- Commissioning key projects while advancing the next phase of speciality chemicals expansion.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.